Companies /Healthcare

Cencora Inc

NYSE: COR Medical Distribution
$321.23
▼ $6.56 (−2.00%) today
Markets closed · 5:37am ET

Q3 2025 Earnings

Reported Aug 6, 2025, 6:34am ET · SEC source
$4.00
Beat +4.23%
EPS · est. $3.84
$80.7B
Beat +0.68%
Revenue · est. $80.1B
+2.4%
Beating market
COR vs S&P since report
5 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−6%−3%0+3%Aug 5Aug 13report 6:34am ETearnings+2.6%−0.4%
−6%−3%0+3%Aug 5Aug 13earnings+2.6%−0.4%
COR −0.4%S&P 500 +2.6%
−6%−3%0+3%Aug 5Aug 13report 6:34am ETearnings+3.7%−0.4%
−6%−3%0+3%Aug 5Aug 13earnings+3.7%−0.4%
COR −0.4%NASDAQ +3.7%
−2.93%
Day of report
−1.90%
Next session
+2.56%
One week
+4.96%
30 days

S&P 500 over the same 30 days: +2.54%.

Did COR Beat Earnings? Q3 2025 Results

Cencora posted a standout fiscal third quarter, with revenue climbing 8.7% year-over-year to $80.66 billion and adjusted diluted EPS jumping 19.8% to $4.00, as the pharmaceutical distributor rode strong demand for GLP-1 class products and specialty pharmaceuticals across its U.S. Healthcare Solutions segment. That domestic engine, which generated $72.88 billion in revenue, saw segment operating income surge 29.1% to $901.79 million, with the January 2025 acquisition of Retina Consultants of America providing a meaningful lift to margins, pushing U.S. gross profit margin to 2.79% from 2.30% a year ago. Internationally, revenue grew 10.5% to $7.79 billion, though segment operating income fell 12.9% to $156.22 million on softness in specialty logistics and consulting. The solid domestic performance gave management confidence to raise full-year adjusted diluted EPS guidance to $15.85 to $16.00, with consolidated adjusted operating income growth now expected at 15% to 16%, even as some analysts flag the stock's elevated valuation as a reason for measured optimism.

Key Takeaways
  • Overall pharmaceutical market growth driven by unit volume increases
  • Increased sales of GLP-1 class products labeled for diabetes and/or weight loss
  • Growth in specialty products distributed to physician practices and health systems
  • January 2025 acquisition of Retina Consultants of America (RCA) contributing to margin expansion
  • LIFO credit of $52.1 million vs. LIFO expense of $6.8 million in prior year quarter
  • Diluted shares outstanding decreased 2.4% due to share repurchases

“Cencora delivered strong financial results in the third fiscal quarter, driven by our pharmaceutical-centric strategy and focus on our growth priorities.”

Cencora CEO, on the earnings call

Forward Guidance & Outlook

Cencora raised its fiscal year 2025 adjusted diluted EPS guidance to $15.85–$16.00 from $15.70–$15.95. Revenue growth is now expected at approximately 9% (narrowed from 8–10%). U.S. Healthcare Solutions segment revenue growth is expected at 9–10% (from 9–11%), with operating income growth of 20–21% (from 17.5–19.5%). International Healthcare Solutions segment revenue growth is expected at 6–7% (from 3–4%), but operating income is now expected to decline approximately 6% (from a decline of 1–4%). Adjusted consolidated operating income growth is expected at 15–16% (from 13.5–15.5%). Adjusted effective tax rate is expected at 20.5–21% (from approximately 21%).

COR YoY Financials

Revenue$80.7B
Gross Profit$2.9B
Operating Income$867.7M
Net Income$687.4M

COR Revenue by Segment

U.S. Healthcare Solutions$72.9B+8.5%
International Healthcare Solutions$7.8B+10.5%
Other

Figures from SEC filings and company reports. Not investment advice.